Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Next Wave For Melanoma

Executive Summary

Melanoma therapy could take another leap forward with the development of another BRAF inhibitor, a MEK inhibitor, and late-stage trials testing combinations against both BRAF options alone.

Advertisement

Related Content

Genentech Catching Up In Melanoma With Cotellic Approval
GSK Overall Survival Data Clinches Role For BRAF/MEK Combo In Melanoma
GSK Overall Survival Data Clinches Role For BRAF/MEK Combo In Melanoma
MEK/BRAF Combo Rests On Survival Benefit
GSK Temporarily Pulls European Application For Tafinlar/Mekinist Combo
GSK’s Mekinist/Tafinlar Combo Pushes The Price Bar
FDA Considers Toxicity Profiles As Meeting Unmet Need In Melanoma
GlaxoSmithKline Deals One-Two Punch With BRAF/MEK Pair

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054518

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel